Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | BCL9 | O00512 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7310199 | 1.00 | MGLL (0.50) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL10201893 | 0.91 | MGLL (0.49) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL2938526 | 0.88 | MMP9 (0.52) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL7174053 | 0.87 | MGLL (0.57) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL6449604 | 0.87 | MGLL (0.52) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL2736300 | 0.85 | MGLL (0.44) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL12249502 | 0.85 | MGLL (0.44) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL18893342 | 0.84 | MGLL (0.46) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL12279815 | 0.83 | ALDH1A1 (0.49) | MGLLGAAHTR2ASMN1; SMN2BCL9 | |
| SCHEMBL7257343 | 0.83 | MGLL (0.57) | MGLLGAAHTR2ASMN1; SMN2BCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006090270-A1 | ACID ADDITION SALT OF 2-ISOPROPYL-4-(((N-METHYL)AMINO)METHYL)THIAZOLE AND ITS?USE IN THE PREPARATION OF RITONAVIR | RANBAXY LABORATORIES LIMITED (US) | 2006-08-31 | — | — | WO | claimed |
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| EP-1302468-B1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2006090270-A1 | ACID ADDITION SALT OF 2-ISOPROPYL-4-(((N-METHYL)AMINO)METHYL)THIAZOLE AND ITS?USE IN THE PREPARATION OF RITONAVIR | RANBAXY LABORATORIES LIMITED (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
| US-6667404-B2 | Carbamylation of 1-amino group of 1,4-amino-3-hydroxybutane derivative with an organocarbonate containing thiazolyl, oxazolyl, isoxazolyl or isothiazolyl substituent | ABBOTT LABORATORIES | 2003-12-23 | — | — | US | disclosed |
| US-20030195362-A1 | Retroviral protease inhibiting compounds | KEMPF DALE J (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1302468-A1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6531610-B1 | Intermediate acylating carbonate | ABBOTT LABORATORIES | 2003-03-11 | — | — | US | disclosed |
| EP-1090914-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2003-01-02 | — | — | EP | disclosed |
| US-5461067-A | For HIV infections | ABBOTT LABORATORIES (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0674513-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0683772-A4 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1995020384-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1995009614-A1 | PHARMACEUTICAL COMPOSITION | ABBOTT LABORATORIES (US) | 1995-04-13 | — | — | WO | disclosed |
| WO-1995007696-A1 | PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1994014436-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | SLC14A1, LPXN, UBXN1 | MGLL 234/4885GAA 465/4885HTR2A 4804/4885 |
| US-20030195362-A1 | Retroviral protease inhibiting compounds | PREP, SERPINB1, PRSS1 | MGLL 2628/4885GAA 112/4885HTR2A 4828/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MGLL 850/4885GAA 91/4885HTR2A 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.